D-serine added to antipsychotics for the treatment of schizophrenia

[1]  R. Kahn,et al.  D-Cycloserine Increases Positive Symptoms in Chronic Schizophrenic Patients When Administered in Addition to Antipsychotics: A Double-Blind, Parallel, Placebo-Controlled Study , 1999, Neuropsychopharmacology.

[2]  J. Coyle,et al.  Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia , 1998, Biological Psychiatry.

[3]  T. Nishikawa,et al.  Characterization of the phencyclidine‐induced increase in prefrontal cortical dopamine metabolism in the rat , 1998, British journal of pharmacology.

[4]  Anil K Malhotra,et al.  Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics , 1997, Neuropsychopharmacology.

[5]  A. Hashimoto,et al.  Free d-aspartate and d-serine in the mammalian brain and periphery , 1997, Progress in Neurobiology.

[6]  S. Hirsch,et al.  Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. , 1997, Archives of general psychiatry.

[7]  C. Tamminga,et al.  Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. , 1997, The American journal of psychiatry.

[8]  R. Tamura,et al.  Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. , 1997, The American journal of psychiatry.

[9]  S. Snyder,et al.  d-Serine as a Neuromodulator: Regional and Developmental Localizations in Rat Brain Glia Resemble NMDA Receptors , 1997, The Journal of Neuroscience.

[10]  K. Narisawa,et al.  Depletion of cerebral D-serine in non-ketotic hyperglycinemia: possible involvement of glycine cleavage system in control of endogenous D-serine. , 1997, Biochemical and biophysical research communications.

[11]  H. Westenberg,et al.  Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients , 1996, Biological Psychiatry.

[12]  J. Coyle,et al.  D-cycloserine added to clozapine for patients with schizophrenia. , 1996, The American journal of psychiatry.

[13]  D. Javitt,et al.  Double-Blind, Placebo-Controlled, Crossover Trial of Glycine Adjuvant Therapy for Treatment-Resistant Schizophrenia , 1996, British Journal of Psychiatry.

[14]  P. Wood,et al.  Formation of d‐Serine from l‐Phosphoserine in Brain Synaptosomes , 1996, Journal of neurochemistry.

[15]  D. Javitt,et al.  Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial , 1996, Biological Psychiatry.

[16]  Joseph T. Coyle,et al.  The Glutamatergic Dysfunction Hypothesis for Schizophrenia , 1996, Harvard review of psychiatry.

[17]  L. Zuck,et al.  Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia , 1995, Neuroreport.

[18]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[19]  J. Kleinman,et al.  Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. , 1995, Archives of general psychiatry.

[20]  J. Krystal,et al.  Glycine Site Agonists of the NMDA Receptor: A Review , 1995 .

[21]  T. Nishikawa,et al.  Anatomical Distribution and Postnatal Changes in Endogenous Free D‐Aspartate and D‐Serine in Rat Brain and Periphery , 1995, The European journal of neuroscience.

[22]  J. Coyle,et al.  Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. , 1995, The American journal of psychiatry.

[23]  K. Wada,et al.  Functional Comparison of d‐Serine and Glycine in Rodents: The Effect on Cloned NMDA Receptors and the Extracellular Concentration , 1995, Journal of neurochemistry.

[24]  A. Halberstadt.  The phencyclidine-glutamate model of schizophrenia. , 1995, Clinical neuropharmacology.

[25]  T. Nishikawa,et al.  Free d-serine in post-mortem brains and spinal cords of individuals with and without neuropsychiatric diseases , 1995, Brain Research.

[26]  D. Javitt,et al.  Pharmacological Augmentation of NMDA Receptor Function for Treatment of Schizophrenia a , 1995, Annals of the New York Academy of Sciences.

[27]  L. Iversen,et al.  The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. , 1994, Journal of medicinal chemistry.

[28]  J. Lindenmayer,et al.  Five‐Factor Model of Schizophrenia Initial Validation , 1994, The Journal of nervous and mental disease.

[29]  R. Konno,et al.  Amino acid levels in D-alanine-administered mutant mice lacking D-amino acid oxidase. , 1994, Metabolism: clinical and experimental.

[30]  D. Javitt,et al.  Amelioration of negative symptoms in schizophrenia by glycine. , 1994, The American journal of psychiatry.

[31]  S. Marder,et al.  Risperidone in the treatment of schizophrenia. , 1994, The American journal of psychiatry.

[32]  T. Nishikawa,et al.  Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat. , 1994, The Journal of pharmacology and experimental therapeutics.

[33]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[34]  E. J. Fletcher,et al.  Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurones. , 1993, European journal of pharmacology.

[35]  T. Nishikawa,et al.  Free d-serine, d-aspartate and d-alanine in central nervous system and serum in mutant mice lacking d-amino acid oxidase , 1993, Neuroscience Letters.

[36]  T. Nishikawa,et al.  Endogenous d‐Serine in Rat Brain: N‐Methyl‐d‐Aspartate Receptor‐Related Distribution and Aging , 1993, Journal of neurochemistry.

[37]  T. Nishikawa,et al.  Determination of free amino acid enantiomers in rat brain and serum by high-performance liquid chromatography after derivatization with N-tert.-butyloxycarbonyl-L-cysteine and o-phthaldialdehyde. , 1992, Journal of chromatography.

[38]  T. Gordh,et al.  The NMDA-receptor antagonist CPP abolishes neurogenic ‘wind-up pain’ after intrathecal administration in humans , 1992, Pain.

[39]  J. Kane.  Clinical Efficacy of Clozapine in Treatment-Refractory Schizophrenia: An Overview , 1992, British Journal of Psychiatry.

[40]  T. Nishikawa,et al.  Stereoselective inhibition by d- and l-alanine of phencyclidine-induced locomotor stimulation in the rat , 1991, Brain Research.

[41]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[42]  Takahashi Kiyohisa,et al.  D-alanine inhibits methamphetamine-induced hyperactivity in rats. , 1991 .

[43]  G. Fisher,et al.  Free D-aspartate and D-alanine in normal and Alzheimer brain , 1991, Brain Research Bulletin.

[44]  R. Dingledine,et al.  Dual effect of glycine on NMDA-induced neurotoxicity in rat cortical cultures , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[45]  Michael V. Johnston,et al.  Physiological and pathophysiological roles of excitatory amino acids during central nervous system development , 1990, Brain Research Reviews.

[46]  P. Contreras.  D-serine antagonized phencyclidine- and MK-801-induced stereotyped behavior and ataxia , 1990, Neuropharmacology.

[47]  Robert W. Buchanan,et al.  The schedule for the deficit syndrome: An instrument for research in schizophrenia , 1989, Psychiatry Research.

[48]  R. Dingledine,et al.  Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes. , 1989, Molecular pharmacology.

[49]  T. Barnes.  A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.

[50]  A. Thomson,et al.  Glycine enhances NMDA-receptor mediated synaptic potentials in neocortical slices , 1989, Nature.

[51]  L. Vyklický,et al.  Regulation of NMDA receptor desensitization in mouse hippocampal neurons by glycine , 1989, Nature.

[52]  S. Deutsch,et al.  A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. , 1989, Clinical neuropharmacology.

[53]  U. Ahlfors,et al.  The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.

[54]  F. Carone,et al.  Urinary loss of glucose, phosphate, and protein by diffusion into proximal straight tubules injured by D-serine and maleic acid. , 1985, Laboratory investigation; a journal of technical methods and pathology.

[55]  W H Oldendorf,et al.  Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. , 1971, The American journal of physiology.

[56]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[57]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[58]  J. Coyle,et al.  A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. , 1999, Archives of general psychiatry.

[59]  D. Javitt,et al.  Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. , 1999, Archives of general psychiatry.

[60]  P. Herrling,et al.  d-CPPene (SDZ EAA-494)—A Competitive NMDA Antagonist: Pharmacology and Results in Humans , 1997 .

[61]  R. Conley,et al.  Evaluation of treatment-resistant schizophrenia. , 1997, Schizophrenia bulletin.

[62]  D. Javitt,et al.  Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. , 1996, Psychopharmacology bulletin.

[63]  S. Heinemann,et al.  Cloned glutamate receptors. , 1994, Annual review of neuroscience.

[64]  C. Cotman,et al.  Excitatory amino acid receptors in schizophrenia. , 1993, Schizophrenia bulletin.

[65]  J. Olney,et al.  Excitotoxic amino acids and neuropsychiatric disorders. , 1990, Annual review of pharmacology and toxicology.

[66]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[67]  H. Meltzer,et al.  Psychopharmacology : the third generation of progress , 1987 .

[68]  Chase Tn.  Drug-induced extrapyramidal disorders. , 1972 .